Michael J. Fox Foundation Commits up to $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
First launched in 2006, TDI is designed exclusively to support and bolster industry-focused efforts on Parkinsonís research as part of MJFFís focus on Ďde-riskingí preclinical PD research for biotech and pharmaceutical companies ó thus expanding and catalyzing industry investments in Parkinsonís drug development. By adding MJFF resources to companiesí own, the Foundation aims to make Parkinsonís therapies a more attractive bet and help to push research further along the pipeline.
Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinsonís disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.
Under the 2009
The first three years of